Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France

Introduction Lung cancer (LC) is the leading cause of death from cancer. Early diagnosis of LC is of paramount importance in terms of prognosis. The health authorities of most countries do not accept screening programmes based on low-dose chest CT (LDCT), especially in Europe, because they are flawed by a high rate of false-positive results, leading to a large number of invasive diagnostic procedures. These authorities advocated further research, including companion biological tests that could enhance the effectiveness of LC screening. The present project aims to validate early diagnosis of LC by detection and characterisation of circulating tumour cells (CTCs) in a peripheral blood sample taken from a prospective cohort of persons at high-risk of LC. Methods and analysis The AIR Project is a prospective, multicentre, double-blinded, cohort study conducted by a consortium of 21 French university centres. The primary objective is to determine the operational values of CTCs for the early detection of LC in a cohort of asymptomatic participants at high risk for LC, that is, smokers and ex-smokers (≥30 pack-years, quitted ≤15 years), aged ≥55 years, with chronic obstructive pulmonary disease (COPD). The study participants will undergo yearly screening rounds for 3 years plus a 1-year follow-up. Each round will include LDCT plus peripheral blood sampling for CTC detection. Assuming 5% prevalence of LC in the studied population and a 10% dropout rate, a total of at least 600 volunteers will be enrolled. Ethics and dissemination The study sponsor is the University Hospital of Nice. The study was approved for France by the ethical committee CPP Sud-Méditerranée V and the ANSM (Ministry of Health) in July 2015. The findings of the trial will be disseminated through peer-reviewed journals and national and international conference presentations. Trial registration number NCT02500693.

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  L. Sequist,et al.  AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. , 2017, American journal of respiratory and critical care medicine.

[3]  Shulin Li,et al.  Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer , 2017, Biological Procedures Online.

[4]  A. Bankier,et al.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. , 2017, Radiology.

[5]  F. Chauvin,et al.  Design and validation of a self-administered questionnaire as an aid to detection of occupational exposure to lung carcinogens. , 2017, Public health.

[6]  Stephanie A Kovalchik,et al.  Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. , 2016, JAMA.

[7]  P. Hofman,et al.  Detection and characterization of circulating tumor cells in lung cancer: Why and how? , 2016, Cancer cytopathology.

[8]  Massimo Bellomi,et al.  miR-Test: a blood test for lung cancer early detection. , 2015, Journal of the National Cancer Institute.

[9]  G. Gazelle,et al.  Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis , 2015, Cancer.

[10]  J. Weissfeld,et al.  Improving selection criteria for lung cancer screening. The potential role of emphysema. , 2015, American journal of respiratory and critical care medicine.

[11]  D. Arenberg.  Searching for red shirts. Emphysema as a lung cancer screening criterion? , 2015, American Journal of Respiratory and Critical Care Medicine.

[12]  B. Celli,et al.  Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. , 2015, American journal of respiratory and critical care medicine.

[13]  F Levi,et al.  European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Marius Ilie,et al.  “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease , 2014, PloS one.

[15]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[16]  David F Yankelevitz,et al.  CT screening for lung cancer: alternative definitions of positive test result based on the national lung screening trial and international early lung cancer action program databases. , 2014, Radiology.

[17]  M. Ashton,et al.  Major Changes , 2014 .

[18]  F. Laurent,et al.  Management strategy of pulmonary nodule in 2013. , 2013, Diagnostic and interventional imaging.

[19]  H. D. de Koning,et al.  European randomized lung cancer screening trials: Post NLST , 2013, Journal of surgical oncology.

[20]  B. Asselain,et al.  Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. , 2013, Lung cancer.

[21]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[22]  A. Didier,et al.  Alternative Processing of the U2 Small Nuclear RNA Produces a 19–22nt Fragment with Relevance for the Detection of Non-Small Cell Lung Cancer in Human Serum , 2013, PloS one.

[23]  E. Quoix,et al.  From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF) , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  C. Marquette,et al.  ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Hopkins,et al.  Diagnosing COPD and targeted lung cancer screening , 2012, European Respiratory Journal.

[26]  Benjamin M. Smith,et al.  Emphysema detected on computed tomography and risk of lung cancer: a systematic review and meta-analysis. , 2012, Lung cancer.

[27]  D. Berry,et al.  Benefits and harms of CT screening for lung cancer: a systematic review. , 2012, JAMA.

[28]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[29]  Fang Zhang,et al.  Effect of Emphysema on Lung Cancer Risk in Smokers: A Computed Tomography–Based Assessment , 2010, Cancer Prevention Research.

[30]  T. Molina,et al.  Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker , 2010, Clinical Cancer Research.

[31]  J. Leader,et al.  Association of radiographic emphysema and airflow obstruction with lung cancer. , 2008, American journal of respiratory and critical care medicine.

[32]  C. Berg,et al.  Lung cancer screening: promise and pitfalls. , 2008, Seminars in oncology nursing.

[33]  Gorka Bastarrika,et al.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. , 2007, Chest.

[34]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  B. Asselain,et al.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. , 2006, The Lancet. Oncology.

[36]  James L Mulshine,et al.  Lung cancer screening. , 2005, The oncologist.

[37]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[38]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[39]  P. Hofman.  Liquid biopsy for early detection of lung cancer , 2017, Current opinion in oncology.

[40]  A. Agustí.  Global Initiative for Chronic Obstructive Lung Disease , 2013 .

[41]  M. L. R. D. Christenson,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[42]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[43]  G. Byrnes,et al.  Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.